Court Denies Lilly, Takeda’s Request to Toss $9 Billion Damage Award Over Actos Bladder Cancer Case

Drug Industry Daily
Eli Lilly and Takeda Pharmaceuticals have lost their appeal to reverse a combined jury award of $9 billion in punitive damages for hiding bladder cancer risks associated with their diabetes drug Actos, but experts say that verdict will likely be reduced.

To View This Article:


Subscribe To Drug Industry Daily